Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Insight Molecular Diagnostics's price to sales ratio was 46.7× on Nov 11, 2026, against 39.9× a year earlier. Over the last 5 years it ranged from 8.9× to 102.9×, with a median of 28.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 46.7× | −2.1 |
| 2025 | Dec 31, 2025 | 48.8× | +3.9 |
| 2024 | Dec 31, 2024 | 44.9× | +30.8 |
| 2023 | Dec 29, 2023 | 14.1× | +5.2 |
| 2022 | Dec 30, 2022 | 8.9× | −34.2 |
| 2021 | Dec 31, 2021 | 43.1× | – |
See a number that looks wrong?